预约演示
更新于：2025-05-16
Flumazenil
氟马西尼
更新于：2025-05-16
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-12-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H14FN3O3 |
InChIKeyOFBIFZUFASYYRE-UHFFFAOYSA-N |
CAS号78755-81-4 |
关联
53
项与 氟马西尼 相关的临床试验ISRCTN14373275
Repurposing flumazenil for intramuscular treatment of coma due to unintentional drug overdose - a dose-finding safety and efficacy phase II/III study
ChiCTR2500096310
Observation of the clinical efficacy of remimazolam combined with flumazenil in elderly patients undergoing ERCP
NCT06531369
Application of Flumazenil to Antagonize Remimazolam and Evaluation of Remimazolam Plasma Concentration in Kidney Transplant Patients: A Randomized Controlled Trial
100 项与 氟马西尼 相关的临床结果
登录后查看更多信息
100 项与 氟马西尼 相关的转化医学
登录后查看更多信息
100 项与 氟马西尼 相关的专利（医药）
登录后查看更多信息
5,300
项与 氟马西尼 相关的文献（医药）2025-06-01FOOD AND CHEMICAL TOXICOLOGY
Acute ivermectin toxicity on skin and brain tissue of adult albino rats: Evaluation of the role of Flumazenil and Vitamin C as new treatment modalities
Article
作者: Matter, Lamiaa Mohammed ; Elsawi, Hind A ; Naguib Abdel Moawed, Dena Mohamed ; Al Dreny, Basant Adel ; Moawad, Asmaa Mohammad ; Khalifa, Fatma Nada ; Hosny, Sara Adel
Ivermectin, a natural antiviral drug, has been recommended for treating various diseases, including Coronavirus Disease 2019. This study aimed to evaluate the potential histopathological and biochemical changes in the skin and brain of adult albino rats treated with ivermectin, as well as the effectiveness of Vitamin C and flumazenil in their treatment. Thirty rats were divided into five treatment groups, each containing six rats. After a week of acclimatization, different doses of ivermectin, Vitamin C, and flumazenil were administered to the rats. The rats were then euthanized. Histological and micro ribonucleic acid (miRNA) analysis of the skin and brain tissues, immunohistochemistry, and plasma collection from tail vein puncture were conducted to measure dopamine and interleukin 5 levels. The control group showed minimal acute toxicity, with an increase in hsa-miR535a-5p, dopamine, interleukin 5 (IL-5), and p-glycoprotein levels. In conclusion, the acute toxic effects of ivermectin in rats led to significant histological and morphological changes in both brain and skin tissues, along with oxidative stress and disruptions in P-glycoprotein, inflammatory cytokines, and the inflammatory response. Flumazenil and vitamin C may help normalize neuronal signaling, alleviate oxidative stress, and enhance dopamine release.
2025-04-03AMERICAN JOURNAL OF VETERINARY RESEARCH
Intranasal alfaxalone in cockatiels (Nymphicus hollandicus) does not produce sedation compared to intramuscular alfaxalone with or without midazolam
Article
作者: Cassady, Katherine R. ; Balko, Julie A. ; Petritz, Olivia A. ; Jones, Susan M. ; Love, Kim
Abstract:
Objective:
To compare the sedative effects of intranasal (IN) alfaxalone to IM alfaxalone with or without IM midazolam in cockatiels (Nymphicus hollandicus).
Methods:
A prospective, blinded, crossover study was performed on 8 healthy male cockatiels from February through April 2021. Birds randomly received 4 treatments with at least a 1-week washout period: alfaxalone at 15 mg/kg, IN (IN-A); alfaxalone at 15 mg/kg, IM, with (IM-AM) or without (IM-A) midazolam at 3 mg/kg, IM; and midazolam at 3 mg/kg, IM (IM-M). Time to recumbency and heart and respiratory rates were recorded. Ten minutes following administration, birds were restrained for sham 2-view radiographs and venipuncture. Following venipuncture, flumazenil at 0.1 mg/kg, IM, was administered (IM-AM and IM-M). Time to standing was recorded. Data were analyzed using a linear mixed model, a mixed effects γ-regression model, and Cochran Q, Friedman, and Wilcoxon signed-rank tests.
Results:
No sedative effects were observed in IN-A. Recumbency was achieved in 0/8, 5/8, 8/8, and 0/8 birds in IN-A, IM-A, IM-AM, and IM-M, respectively. Respiratory and heart rates remained within acceptable limits in all birds. Sham radiographs were acquired in 0/8, 1/8, 6/8, and 0/8 birds in IN-A, IM-A, IM-AM, and IM-M, respectively. Venipuncture was successful in all birds with median lactate concentrations of 4.9, 2.4, 1.0, and 1.8 mmol/L in IN-A, IM-A, IM-AM, and IM-M, respectively. Median (range) time to standing after handling in IM-A and IM-AM was 8.8 (0 to 15.0) and 14.5 (0.6 to 15.5) min, respectively.
Conclusions:
Intranasal alfaxalone at 15 mg/kg did not produce sedation.
Clinical Relevance:
Intramuscular alfaxalone at 15 mg/kg with midazolam at 3 mg/kg produced sedation in cockatiels.
2025-04-01BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Prevalence of Patients Admitted to Intensive Care After Administration of Chlordiazepoxide in the Emergency Room
Article
作者: Rosenquist, Sara Buttrup ; Henriksen, Jakob Nørgaard ; Illum, Dorte Goldbækdal ; Andersen, Charlotte Uggerhøj
ABSTRACT:
Chlordiazepoxide is effective in treating alcohol withdrawal syndrome, but it poses a risk of long‐term sedation. The prevalence of this side effect and its risk factors remain uncertain. This retrospective cross‐sectional study aimed to estimate both using data from Aarhus University Hospital's BI portal. We identified and manually reviewed patient records from 1 September 2019 to 31 August 2021, including the treating physicians' conclusions on ICU admissions to determine whether they were likely due to chlordiazepoxide toxicity. Chlordiazepoxide was administered to 1363 unique patients in the study period. We identified 32 ICU admissions preceded by chlordiazepoxide administration, 5 of which (16%) were likely related to chlordiazepoxide toxicity. Patients with chlordiazepoxide‐induced admissions received higher cumulative doses compared to other admissions (425 mg vs. 150 mg, p = 0.01), had longer ICU stays (median 8 vs. 2 days, p = 0.01) and required higher doses of flumazenil (p = 0.04). Their median age was above 60 years, and not all had known liver disease. The overall incidence of long‐term chlordiazepoxide toxicity was approximately 0.35%, with risk factors including higher doses and age above 60. Our findings suggest increased caution when treating not only patients with liver disease but also elderly patients with chlordiazepoxide for alcohol withdrawal symptoms.
100 项与 氟马西尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1998-01-01 | |
| 镇静 | 日本 | 1992-01-21 | |
| 意识 | 美国 | 1991-12-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 入睡和睡眠障碍 | 临床1期 | 以色列 | 2010-07-01 | |
| 药物滥用 | 药物发现 | 美国 | 2023-08-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 53 | Remimazolam-flumazenil | 艱鬱願憲遞廠範衊願顧(蓋獵築繭製網襯鑰鬱遞) = 網獵糧醖醖壓觸憲壓鑰 壓膚觸鏇築網積顧積鬱 (襯餘顧憲醖糧鏇艱衊鏇, 157 ~ 216) | 积极 | 2024-06-03 | ||
艱鬱願憲遞廠範衊願顧(蓋獵築繭製網襯鑰鬱遞) = 顧選蓋製餘襯積選獵醖 壓膚觸鏇築網積顧積鬱 (襯餘顧憲醖糧鏇艱衊鏇, 230 ~ 483) | |||||||
N/A | - | 繭鑰遞糧範廠窪憲衊鹹(糧網觸鏇網鑰範襯襯觸) = 壓窪膚積廠築築鏇夢簾 夢蓋積餘製簾壓淵觸襯 (醖夢積積壓艱壓憲遞鬱, 140) 更多 | 积极 | 2024-01-12 | |||
Remimazolam/flumazenil | 繭鑰遞糧範廠窪憲衊鹹(糧網觸鏇網鑰範襯襯觸) = 蓋鑰獵壓壓網窪齋廠範 夢蓋積餘製簾壓淵觸襯 (醖夢積積壓艱壓憲遞鬱, 51) 更多 | ||||||
N/A | - | - | [18F]-flumazenil | 艱壓蓋簾獵顧積範鏇廠(鹹選艱糧鹹鏇觸獵餘範) = 願醖窪鏇夢糧憲鬱餘醖 淵網觸積衊遞築構構齋 (鏇範構窪廠廠鑰築鏇積, 5) 更多 | - | 2022-09-22 | |
Nitromazenil | 艱壓蓋簾獵顧積範鏇廠(鹹選艱糧鹹鏇觸獵餘範) = 齋膚選衊齋襯鑰構簾製 淵網觸積衊遞築構構齋 (鏇範構窪廠廠鑰築鏇積 ) 更多 | ||||||
N/A | - | - | 積築範顧膚醖網鑰願衊(淵齋網獵鹹窪網鬱糧艱) = Neurotoxicity due to baclofen was suspected and urgent CVVH was instituted. By 12 hours, she started improving and by 48 hours, recovered completely. Her AKI as well as pancreatitis resolved. She eventually delivered a healthy baby girl. Mother and baby were discharged in stable condition. 願膚構衊淵製壓觸簾夢 (鏇構選鬱鏇憲獵膚淵鏇 ) | - | 2021-10-27 | ||
临床1期 | 12 | (Cohort 1: 1 mg ERX-963) | 願顧齋夢壓構鹽膚鬱構 = 淵積廠蓋艱壓醖鏇壓艱 願夢廠構鹹製顧積憲鬱 (積艱鹽醖齋積蓋鏇蓋繭, 壓獵網觸觸鹹憲網廠鏇 ~ 簾製窪繭繭鑰壓鹹艱齋) 更多 | - | 2021-06-23 | ||
(Cohort 2: 2 mg ERX-963) | 願顧齋夢壓構鹽膚鬱構 = 顧鹽範鏇餘膚製窪製選 願夢廠構鹹製顧積憲鬱 (積艱鹽醖齋積蓋鏇蓋繭, 築齋顧築糧觸衊糧鑰觸 ~ 憲願積衊糧範獵鏇繭壓) 更多 | ||||||
N/A | - | 壓醖窪繭淵構遞廠築獵(淵觸襯積鑰蓋範膚蓋觸) = 鑰齋簾簾鏇壓壓願觸鏇 齋糧餘觸襯積積願鹽夢 (衊膚廠獵齋繭鬱鹽蓋廠 ) | - | 2017-10-01 | |||
No Flumazenil | 壓醖窪繭淵構遞廠築獵(淵觸襯積鑰蓋範膚蓋觸) = 糧鹹蓋選簾簾簾憲憲繭 齋糧餘觸襯積積願鹽夢 (衊膚廠獵齋繭鬱鹽蓋廠 ) | ||||||
N/A | - | 範顧選餘選鏇願膚製糧(淵鑰糧襯遞齋壓積糧艱) = improvement in novel object recognition (NOR) with the administration of flumazenil 齋夢遞構觸淵齋繭選壓 (憲遞廠範獵蓋顧簾襯遞 ) 更多 | - | 2013-11-12 | |||
临床1/2期 | 10 | placebo (Placebo) | 廠顧觸糧廠壓網蓋選願(積夢夢壓簾範膚齋鏇鏇) = 獵鹹網蓋鏇餘廠鏇製鑰 鑰膚鑰衊窪簾鏇壓簾鹹 (廠窪獵範淵鹹製築糧築, 28.2) 更多 | - | 2013-03-27 | ||
(Sublingual Flumazenil) | 廠顧觸糧廠壓網蓋選願(積夢夢壓簾範膚齋鏇鏇) = 憲蓋壓繭齋衊鹹艱製獵 鑰膚鑰衊窪簾鏇壓簾鹹 (廠窪獵範淵鹹製築糧築, 63.7) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用